- Home
- ENVB vs ISPC Comparison
ENVB vs ISPC Comparison
Compare ENVB & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- ISPC
- Stock Information
- Founded
- ENVB 1994
- ISPC 2009
- Country
- ENVB United States
- ISPC United States
- Employees
- ENVB N/A
- ISPC N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- ENVB Health Care
- ISPC Health Care
- Exchange
- ENVB Nasdaq
- ISPC Nasdaq
- Market Cap
- ENVB 3.1M
- ISPC 3.1M
- IPO Year
- ENVB N/A
- ISPC 2021
- Fundamental
- Price
- ENVB $1.29
- ISPC $0.96
- Analyst Decision
- ENVB Strong Buy
- ISPC
- Analyst Count
- ENVB 1
- ISPC 0
- Target Price
- ENVB $10.00
- ISPC N/A
- AVG Volume (30 Days)
- ENVB 225.8K
- ISPC 49.0K
- Earning Date
- ENVB 08-11-2025
- ISPC 08-05-2025
- Dividend Yield
- ENVB N/A
- ISPC N/A
- EPS Growth
- ENVB N/A
- ISPC N/A
- EPS
- ENVB N/A
- ISPC N/A
- Revenue
- ENVB N/A
- ISPC $8,058,631.00
- Revenue This Year
- ENVB N/A
- ISPC $35.93
- Revenue Next Year
- ENVB N/A
- ISPC N/A
- P/E Ratio
- ENVB N/A
- ISPC N/A
- Revenue Growth
- ENVB N/A
- ISPC N/A
- 52 Week Low
- ENVB $1.01
- ISPC $0.95
- 52 Week High
- ENVB $11.55
- ISPC $11.80
- Technical
- Relative Strength Index (RSI)
- ENVB 45.37
- ISPC 32.03
- Support Level
- ENVB $1.18
- ISPC $0.97
- Resistance Level
- ENVB $1.31
- ISPC $1.29
- Average True Range (ATR)
- ENVB 0.07
- ISPC 0.08
- MACD
- ENVB 0.02
- ISPC -0.03
- Stochastic Oscillator
- ENVB 46.56
- ISPC 2.63
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.